ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb will pay $300 million up front to acquire IFM Therapeutics, a developer of small-molecule drugs that target the innate immune system, the body’s first line of immunological defense. IFM investors could receive up to $1 billion more if the company’s lead molecules reach the market. BMS has been amassing immunology and immuno-oncology compounds, but they try to harness primarily the adaptive immune system. With this deal, BMS gains two preclinical cancer programs—NLRP3 agonists and STING agonists—intended to amp up innate immune response.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X